Varenicline decreases alcohol consumption in heavy-drinking smokers

  title={Varenicline decreases alcohol consumption in heavy-drinking smokers},
  author={Jennifer M Mitchell and Candice H. Teague and Andrew S. Kayser and Selena E Bartlett and Howard L Fields},
Emerging evidence suggests that the α4β2 form of the nicotinic acetylcholine receptor (nAChR) modulates the rewarding effects of alcohol. The nAChR α4β2 subunit partial agonist varenicline (Chantix™), which is approved by the Food and Drug Administration for smoking cessation, also decreases ethanol consumption in rodents (Steensland et al., Proc Natl Acad Sci U S A 104:12518–12523, 2007) and in human laboratory and open-label studies (Fucito et al., Psychopharmacology (Berl) 215:655–663, 2011… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 60 extracted citations


Publications referenced by this paper.
Showing 1-10 of 33 references

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

  • C Bouza, M Angeles, A Magro, A Muñoz, J Amate
  • Addiction
  • 2004
Highly Influential
1 Excerpt

Similar Papers

Loading similar papers…